Daiichi’s Edoxaban A-Fib Claim May Be Limited By Renal Function
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clinical reviewers recommend approval of the Factor Xa inhibitor only for patients with renal impairment because of adverse efficacy results in patients with normal kidney function; at an Oct. 30 meeting, the cardio-renal advisory committee also will be asked to consider approval at a higher, untested dose.
You may also be interested in...
Daiichi’s Edoxaban Wins FDA Panel Nod On Approval But Mixed Verdict On Population, Dose
Cardio-renal committee votes 9-1 for approval of Daiichi’s anticoagulant for stroke risk reduction in patients with nonvalvular atrial fibrillation, but only five panelists said the currently proposed 60 mg dose should be approved for patients with normal renal function given adverse efficacy results in this subpopulation.
Daiichi’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto
Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.